EARLIER CANCER DETECTION.
- Mar 6, 2018
Clinical Genomics Pathology Inc. receives licensure from Florida Agency for Healthcare Administration
- Feb 1, 2018
Pivotal study reports InSure® FIT™ offers superior sensitivity for colorectal cancer screening
- Jan 18, 2018
Clinical Genomics appoints Tadd Lazarus, MD, as Chief Medical Officer
Clinical Genomics develops innovative products for colorectal cancer diagnosis. Our passion is to introduce advanced healthcare solutions to address unmet needs. With a broad intellectual property portfolio including more than 95 patents, Clinical Genomics delivers products to improve early cancer detection and cancer recurrence monitoring.
CLINICAL GENOMICS HAS DEVELOPED COLVERA, A GENOMIC BLOOD TEST TO DIAGNOSE COLORECTAL CANCER RECURRENCE AT THE EARLIEST, MOST TREATABLE STAGES.
Clinical Genomics is investing in technologies and clinical research that deliver better options to healthcare practitioners and lead to improved clinical outcomes for patients.